Patient navigation for colorectal cancer screening in deprived areas: the COLONAV cluster randomized controlled trial.

Colorectal cancer screening Complex interventions Health inequalities Patient navigation Population health intervention research Randomized control trial

Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
06 Jan 2023
Historique:
received: 13 05 2022
accepted: 29 09 2022
entrez: 7 1 2023
pubmed: 8 1 2023
medline: 11 1 2023
Statut: epublish

Résumé

The objective of this study was to assess the effectiveness of a Patient Navigation Intervention targeting deprived patients for Colo-Rectal Cancer (CRC) screening participation. A cluster randomized controlled trial was conducted in 5 districts. Peer Lay Patient Navigators were recruited to operate in deprived areas. Eligible participants had to be between 50 and 74 years old, live in these deprived areas and receive an invitation to the nationally organized Colo-Rectal Cancer (CRC) screening during the study period. The theory-driven navigation intervention was deployed for 18 months. A population Health Intervention Research assessment method was used to assess effectiveness and context interaction. The primary criterion was screening participation at 12 months. Twenty-four thousand two hundred eighty-one individuals were included inside 40 clusters. The increase in participation in the intervention group was estimated at 23%, (ORa = 1.23, CI95% [1.07-1.41], p = 0.003). For the subgroup of individuals who participated, the time delay to participating was reduced by 26% (ORa = 0.74, CI95% [0.57-0.96], p = 0.021). Main factors modulating the effect of the intervention were: closeness of navigator profiles to the targeted population, navigators' abilities to adapt their modus operandi, and facilitating attachment structure. The ColoNav Intervention succeeded in demonstrating its effectiveness, for CRC screening. Patient Navigation should be disseminate with broader health promotion goals in order to achieve equity in health care. clinicaltrials.gov NCT02369757 24/02/2015.

Sections du résumé

BACKGROUND BACKGROUND
The objective of this study was to assess the effectiveness of a Patient Navigation Intervention targeting deprived patients for Colo-Rectal Cancer (CRC) screening participation.
METHODS METHODS
A cluster randomized controlled trial was conducted in 5 districts. Peer Lay Patient Navigators were recruited to operate in deprived areas. Eligible participants had to be between 50 and 74 years old, live in these deprived areas and receive an invitation to the nationally organized Colo-Rectal Cancer (CRC) screening during the study period. The theory-driven navigation intervention was deployed for 18 months. A population Health Intervention Research assessment method was used to assess effectiveness and context interaction. The primary criterion was screening participation at 12 months.
RESULTS RESULTS
Twenty-four thousand two hundred eighty-one individuals were included inside 40 clusters. The increase in participation in the intervention group was estimated at 23%, (ORa = 1.23, CI95% [1.07-1.41], p = 0.003). For the subgroup of individuals who participated, the time delay to participating was reduced by 26% (ORa = 0.74, CI95% [0.57-0.96], p = 0.021). Main factors modulating the effect of the intervention were: closeness of navigator profiles to the targeted population, navigators' abilities to adapt their modus operandi, and facilitating attachment structure.
CONCLUSION CONCLUSIONS
The ColoNav Intervention succeeded in demonstrating its effectiveness, for CRC screening. Patient Navigation should be disseminate with broader health promotion goals in order to achieve equity in health care.
TRIAL REGISTRATION BACKGROUND
clinicaltrials.gov NCT02369757 24/02/2015.

Identifiants

pubmed: 36609248
doi: 10.1186/s12885-022-10169-3
pii: 10.1186/s12885-022-10169-3
pmc: PMC9817361
doi:

Banques de données

ClinicalTrials.gov
['NCT02369757']

Types de publication

Randomized Controlled Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

21

Subventions

Organisme : Institut National Du Cancer
ID : NA
Organisme : Institut National Du Cancer
ID : NA
Organisme : Institut National Du Cancer
ID : NA
Organisme : Institut National Du Cancer
ID : NA
Organisme : Institut National Du Cancer
ID : NA
Organisme : Institut National Du Cancer
ID : NA
Organisme : Institut National Du Cancer
ID : NA
Organisme : Ligue Contre le Cancer
ID : NA

Informations de copyright

© 2023. The Author(s).

Références

J Cancer Educ. 2018 Apr;33(2):251-259
pubmed: 27878766
J Gen Intern Med. 2009 Feb;24(2):211-7
pubmed: 19067085
Eur J Cancer Prev. 2019 Jan;28(1):27-32
pubmed: 29176350
BMJ. 2008 Sep 29;337:a1655
pubmed: 18824488
Lancet. 2016 Feb 20;387(10020):724-6
pubmed: 26680216
BMJ. 2015 Mar 19;350:h1258
pubmed: 25791983
Prev Med. 2016 Dec;93:198-203
pubmed: 27765660
Lancet. 2010 Mar 20;375(9719):1030-47
pubmed: 20304247
Arch Intern Med. 2008 Jun 23;168(12):1317-24
pubmed: 18574089
Can J Public Health. 2009 Jan-Feb;100(1):Suppl I8-14
pubmed: 19263977
Prev Med. 2017 Oct;103:76-83
pubmed: 28823681
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645
Br J Cancer. 2008 Mar 11;98(5):1012-9
pubmed: 18283307
Med Care. 2005 Jun;43(6):551-7
pubmed: 15908849
Cancer. 2011 Aug;117(15 Suppl):3603-17
pubmed: 21780095
JAMA Intern Med. 2018 Dec 1;178(12):1645-1658
pubmed: 30326005
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
J Epidemiol Community Health. 2010 Apr;64(4):318-24
pubmed: 19740776
Eur J Public Health. 2016 Feb;26(1):158-68
pubmed: 26370437
N Engl J Med. 2008 Jun 5;358(23):2468-81
pubmed: 18525043
BMC Cancer. 2016 Jul 07;16:416
pubmed: 27388807
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Evaluation (Lond). 2016 Jul;22(3):286-303
pubmed: 27478401
Soc Sci Med. 2012 Dec;75(12):2299-306
pubmed: 22989491
Prev Med. 2014 Apr;61:100-5
pubmed: 24287122
CA Cancer J Clin. 2019 May;69(3):184-210
pubmed: 30875085
Endoscopy. 2013;45(1):51-9
pubmed: 23212726

Auteurs

A Bourmaud (A)

Clinical Epidemiology Unit, Robert Debré Hospital, AP-HP, and INSERM CIC-EC 1426 and INSERM ECEVE 1123, University of Paris, 48 Bd Sérurier, 75 019, Paris, France. aurelie.bourmaud@aphp.fr.
Public Health Department, Hygée Centre, Lucien Neuwirth Cancer Institute, Saint Priest en Jarez, France and Inserm, Clinical Investigation Center 1408, 42055, Saint-Etienne, France. aurelie.bourmaud@aphp.fr.
Quality Safety Performance in Health (HESPER) EA7425, Lyon 1 University, Lyon, France. aurelie.bourmaud@aphp.fr.

Y Benoist (Y)

Unité de Recherche en Sciences Humaines Et Sociales (URSHS) Institut Gustave Roussy, Paris, France.

F Tinquaut (F)

Public Health Department, Hygée Centre, Lucien Neuwirth Cancer Institute, Saint Priest en Jarez, France and Inserm, Clinical Investigation Center 1408, 42055, Saint-Etienne, France.

C Allary (C)

Public Health Department, Hygée Centre, Lucien Neuwirth Cancer Institute, Saint Priest en Jarez, France and Inserm, Clinical Investigation Center 1408, 42055, Saint-Etienne, France.

J Ramone-Louis (J)

COACTIS EA 4161 - Centre de Recherche en Gestion - Research Center in Management Science ISH and Faculty of Economics and Management, Lumière Lyon 2 University, Lyon, France.

M Oriol (M)

Public Health Department, Hygée Centre, Lucien Neuwirth Cancer Institute, Saint Priest en Jarez, France and Inserm, Clinical Investigation Center 1408, 42055, Saint-Etienne, France.

J Kalecinski (J)

Public Health Department, Hygée Centre, Lucien Neuwirth Cancer Institute, Saint Priest en Jarez, France and Inserm, Clinical Investigation Center 1408, 42055, Saint-Etienne, France.
Quality Safety Performance in Health (HESPER) EA7425, Lyon 1 University, Lyon, France.

V Dutertre (V)

Public Health Department, Hygée Centre, Lucien Neuwirth Cancer Institute, Saint Priest en Jarez, France and Inserm, Clinical Investigation Center 1408, 42055, Saint-Etienne, France.

N Lechopier (N)

Lyon1 University, Lyon, France.
UMR S2HEP, French Education Institute, Ecole Normale Supérieure de Lyon, Lyon, France.

M Pommier (M)

UMR S2HEP, French Education Institute, Ecole Normale Supérieure de Lyon, Lyon, France.

S Rousseau (S)

Public Health Department, Hygée Centre, Lucien Neuwirth Cancer Institute, Saint Priest en Jarez, France and Inserm, Clinical Investigation Center 1408, 42055, Saint-Etienne, France.
Unité de Recherche en Sciences Humaines Et Sociales (URSHS) Institut Gustave Roussy, Paris, France.

A Dumas (A)

Clinical Epidemiology Unit, Robert Debré Hospital, AP-HP, and INSERM CIC-EC 1426 and INSERM ECEVE 1123, University of Paris, 48 Bd Sérurier, 75 019, Paris, France.
Unité de Recherche en Sciences Humaines Et Sociales (URSHS) Institut Gustave Roussy, Paris, France.

P Amiel (P)

Clinical Epidemiology Unit, Robert Debré Hospital, AP-HP, and INSERM CIC-EC 1426 and INSERM ECEVE 1123, University of Paris, 48 Bd Sérurier, 75 019, Paris, France.
Unité de Recherche en Sciences Humaines Et Sociales (URSHS) Institut Gustave Roussy, Paris, France.

V Regnier (V)

Public Health Department, Hygée Centre, Lucien Neuwirth Cancer Institute, Saint Priest en Jarez, France and Inserm, Clinical Investigation Center 1408, 42055, Saint-Etienne, France.
Quality Safety Performance in Health (HESPER) EA7425, Lyon 1 University, Lyon, France.

V Buthion (V)

COACTIS EA 4161 - Centre de Recherche en Gestion - Research Center in Management Science ISH and Faculty of Economics and Management, Lumière Lyon 2 University, Lyon, France.

F Chauvin (F)

Public Health Department, Hygée Centre, Lucien Neuwirth Cancer Institute, Saint Priest en Jarez, France and Inserm, Clinical Investigation Center 1408, 42055, Saint-Etienne, France.
Quality Safety Performance in Health (HESPER) EA7425, Lyon 1 University, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH